EPLIN as a Molecular Target of Genistein in Preventing Prostate Cancer Metastasis

EPLIN 作为金雀异黄素预防前列腺癌转移的分子靶点

基本信息

  • 批准号:
    8854250
  • 负责人:
  • 金额:
    $ 10.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-07-09 至 2016-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): EPLIN as a Molecular Target of Genistein In Preventing Prostate Cancer Metastasis Genistein, a major dietary isoflavone whose consumption is associated with decreased rate of metastasis and reduced risk of mortality in patients, has emerged as a promising inhibitor of PCa metastasis. Nonetheless, the mechanism of action of genistein in blocking metastatic cascade in cancer cells remains largely unknown. In this application, we will test the hypothesis that the induction of EPLIN is a major mechanism wherein genistein inhibits the acquisition of invasiveness by PCa cells and prevents tumor metastasis. We proposed two Specific Aims. In Aim 1, we will elucidate the molecular mechanism by which genistein upregulates EPLIN and inhibits EMT in PCa cells. The hypothesis is that genistein induces EPLIN expression at transcriptional level, thereby inhibiting EMT and suppressing invasive phenotypes in PCa cells. We will determine whether genistein activates EPLIN promoter by inhibiting Snail-dependent repression of EPLIN promoter. The in vitro effects of genistein on EMT and invasiveness of PCa cells will be examined. This Aim will elucidate a novel mechanism of action of genistein in blocking the metastatic cascade in PCa cells. In Aim 2, we will determine the in vivo effects of genistein in upregulating EPLIN and preventing metastasis in pre-clinical PCa models. The hypothesis is that in vivo administration of genistein could effectively increase EPLIN expression and significantly reduce metastatic incidence in animal models. Two experimental models for PCa metastasis, i.e., TRAMP mice and orthotopic inoculation of PCa cells in SCID mice, will be used to evaluate the in vivo efficacy of genistein in upregulating EPLIN, inhibiting EMT and reducing metastatic incidence. These studies will validate EPLIN as a major molecular target of genistein, which could be exploited clinically for preventing PCa metastasis.
染料木黄酮是一种主要的膳食异黄酮,食用染料木黄酮可降低转移率和患者死亡风险,它已成为一种有希望的前列腺癌转移抑制剂。尽管如此,染料木素在阻断癌细胞转移级联中的作用机制仍不甚清楚。在这个应用中,我们将验证一个假设,即诱导EPLIN是染料木素抑制PCa细胞获得侵袭性并阻止肿瘤转移的主要机制。我们提出了两个具体目标。在Aim 1中,我们将阐明染料木素在PCa细胞中上调EPLIN和抑制EMT的分子机制。假设染料木素在转录水平诱导EPLIN表达,从而抑制EMT,抑制PCa细胞的侵袭性表型。我们将通过抑制蜗牛依赖的EPLIN启动子抑制来确定染料木素是否激活EPLIN启动子。我们将研究染料木素对前列腺癌细胞EMT和侵袭性的体外影响。本研究旨在阐明染料木素阻断前列腺癌细胞级联转移的新机制。在Aim 2中,我们将在临床前PCa模型中确定染料木素上调EPLIN和预防转移的体内作用。我们的假设是,在动物模型中,给药染料木素可以有效地增加EPLIN的表达并显著降低转移发生率。我们将采用TRAMP小鼠和SCID小鼠原位接种PCa细胞两种PCa转移实验模型,来评估染料木素在体内上调EPLIN、抑制EMT和降低转移发生率的作用。这些研究将验证EPLIN是染料木素的主要分子靶点,可用于临床预防前列腺癌转移。

项目成果

期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Epithelial protein lost in neoplasm (EPLIN): Beyond a tumor suppressor.
肿瘤中丢失的上皮蛋白 (EPLIN):超越肿瘤抑制因子。
  • DOI:
    10.1016/j.gendis.2017.03.002
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    6.8
  • 作者:
    Wu,Daqing
  • 通讯作者:
    Wu,Daqing
Pomegranate extract inhibits the bone metastatic growth of human prostate cancer cells and enhances the in vivo efficacy of docetaxel chemotherapy.
石榴提取物抑制人前列腺癌细胞的骨转移生长,增强多西紫杉醇化疗的体内疗效。
  • DOI:
    10.1002/pros.22769
  • 发表时间:
    2013
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Wang,Yanru;Zhang,Shumin;Iqbal,Shareen;Chen,Zhengjia;Wang,Xiaojing;Wang,YongqiangA;Liu,David;Bai,Kevin;Ritenour,Chad;Kucuk,Omer;Wu,Daqing
  • 通讯作者:
    Wu,Daqing
Mifepristone Has Limited Activity to Enhance the In Vivo Efficacy of Docetaxel and Enzalutamide Against Bone Metastatic and Castration-Resistant Prostate Cancer.
  • DOI:
    10.21873/anticanres.12074
  • 发表时间:
    2017-11
  • 期刊:
  • 影响因子:
    2
  • 作者:
    Yang Yang-Yang;Xin Li;K. Mamouni;O. Kucuk;Daqing Wu
  • 通讯作者:
    Yang Yang-Yang;Xin Li;K. Mamouni;O. Kucuk;Daqing Wu
Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative.
多西紫杉醇和 BKM1644(一种氨基二磷酸盐衍生物)的组合可抑制人前列腺癌的骨骼生长。
  • DOI:
    10.18632/oncotarget.8481
  • 发表时间:
    2016
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Zhang,Shumin;Gera,Lajos;Mamouni,Kenza;Li,Xin;Chen,Zhengjia;Kucuk,Omer;Wu,Daqing
  • 通讯作者:
    Wu,Daqing
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAQING WU其他文献

DAQING WU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAQING WU', 18)}}的其他基金

Targeting chemoresistant prostate cancer with novel EED inhibitors
使用新型 EED 抑制剂靶向化疗耐药性前列腺癌
  • 批准号:
    10444602
  • 财政年份:
    2022
  • 资助金额:
    $ 10.38万
  • 项目类别:
Targeting chemoresistant prostate cancer with novel EED inhibitors
使用新型 EED 抑制剂靶向化疗耐药性前列腺癌
  • 批准号:
    10590661
  • 财政年份:
    2022
  • 资助金额:
    $ 10.38万
  • 项目类别:
Diversity Supplement: Targeting chemoresistant prostate cancer with novel EED inhibitors
多样性补充:用新型 EED 抑制剂靶向化疗耐药性前列腺癌
  • 批准号:
    10747516
  • 财政年份:
    2022
  • 资助金额:
    $ 10.38万
  • 项目类别:
Small-molecule therapy for metastatic castration-resistant prostate cancer
转移性去势抵抗性前列腺癌的小分子治疗
  • 批准号:
    10325729
  • 财政年份:
    2017
  • 资助金额:
    $ 10.38万
  • 项目类别:
Small-molecule therapy for metastatic castration-resistant prostate cancer
转移性去势抵抗性前列腺癌的小分子治疗
  • 批准号:
    10472020
  • 财政年份:
    2017
  • 资助金额:
    $ 10.38万
  • 项目类别:
Small-molecule therapy for metastatic prostate cancer
转移性前列腺癌的小分子治疗
  • 批准号:
    9407585
  • 财政年份:
    2017
  • 资助金额:
    $ 10.38万
  • 项目类别:
A Dietary Supplement As Adjunct Therapy In Castration-Resistant Prostate Cancer
膳食补充剂作为去势抵抗性前列腺癌的辅助治疗
  • 批准号:
    8834755
  • 财政年份:
    2015
  • 资助金额:
    $ 10.38万
  • 项目类别:
EPLIN as a Molecular Target of Genistein in Preventing Prostate Cancer Metastasis
EPLIN 作为金雀异黄素预防前列腺癌转移的分子靶点
  • 批准号:
    8386046
  • 财政年份:
    2012
  • 资助金额:
    $ 10.38万
  • 项目类别:
EPLIN as a Molecular Target of Genistein in Preventing Prostate Cancer Metastasis
EPLIN 作为金雀异黄素预防前列腺癌转移的分子靶点
  • 批准号:
    8507638
  • 财政年份:
    2012
  • 资助金额:
    $ 10.38万
  • 项目类别:
Enhancement of Cancer Research at Clark Atlanta University
克拉克亚特兰大大学癌症研究的加强
  • 批准号:
    10376107
  • 财政年份:
    1997
  • 资助金额:
    $ 10.38万
  • 项目类别:

相似国自然基金

Kidney injury molecular(KIM-1)介导肾小管上皮细胞自噬在糖尿病肾病肾间质纤维化中的作用
  • 批准号:
    81300605
  • 批准年份:
    2013
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
Molecular Plant
  • 批准号:
    31224801
  • 批准年份:
    2012
  • 资助金额:
    20.0 万元
  • 项目类别:
    专项基金项目
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
  • 批准号:
    31070748
  • 批准年份:
    2010
  • 资助金额:
    34.0 万元
  • 项目类别:
    面上项目
Molecular Plant
  • 批准号:
    31024802
  • 批准年份:
    2010
  • 资助金额:
    20.0 万元
  • 项目类别:
    专项基金项目
Cellular & Molecular Immunology
  • 批准号:
    30824806
  • 批准年份:
    2008
  • 资助金额:
    20.0 万元
  • 项目类别:
    专项基金项目

相似海外基金

Identification of the molecular and cellular mechanisms driving cardiac fibrosis: A novel ex-vivo approach to target identification and validation
驱动心脏纤维化的分子和细胞机制的鉴定:一种新颖的体外靶标鉴定和验证方法
  • 批准号:
    NC/X001733/1
  • 财政年份:
    2023
  • 资助金额:
    $ 10.38万
  • 项目类别:
    Training Grant
Cell-type specific molecular and functional analyses to target dorsal horn pain circuitry in mice and non-human primates
针对小鼠和非人类灵长类动物背角疼痛回路的细胞类型特异性分子和功能分析
  • 批准号:
    10863324
  • 财政年份:
    2023
  • 资助金额:
    $ 10.38万
  • 项目类别:
Molecular target and circuitry underlying the preclinical effects of psychedelics in models of opioid use disorder
阿片类药物使用障碍模型中迷幻药临床前作用的分子靶点和电路
  • 批准号:
    10751173
  • 财政年份:
    2023
  • 资助金额:
    $ 10.38万
  • 项目类别:
Designing cyclic peptide with target protein selection based on mixed-solvent molecular dynamics simulation
基于混合溶剂分子动力学模拟的目标蛋白选择环肽设计
  • 批准号:
    23H03495
  • 财政年份:
    2023
  • 资助金额:
    $ 10.38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
ATIC is a novel molecular target in diffuse intrinsic pontine glioma
ATIC是弥漫性内源性脑桥胶质瘤的新型分子靶点
  • 批准号:
    10712984
  • 财政年份:
    2023
  • 资助金额:
    $ 10.38万
  • 项目类别:
Tailor-Made Molecular Chaperones to Target Protein Misfolding
针对蛋白质错误折叠的定制分子伴侣
  • 批准号:
    10717818
  • 财政年份:
    2023
  • 资助金额:
    $ 10.38万
  • 项目类别:
Molecular Glues to Target RAS-MAPK Driven Cancers
分子胶靶向 RAS-MAPK 驱动的癌症
  • 批准号:
    10880005
  • 财政年份:
    2023
  • 资助金额:
    $ 10.38万
  • 项目类别:
A New Molecular Target to Enhance Poststroke Cognitive Recovery
增强中风后认知恢复的新分子靶点
  • 批准号:
    10658539
  • 财政年份:
    2023
  • 资助金额:
    $ 10.38万
  • 项目类别:
Tissue Engineering of 3D bone marrow niche for hematopoietic stem cells vs acute myeloid leukemia stem cell molecular target and therapeutics discovery
造血干细胞 3D 骨髓生态位的组织工程与急性髓系白血病干细胞分子靶标和治疗发现
  • 批准号:
    468535
  • 财政年份:
    2022
  • 资助金额:
    $ 10.38万
  • 项目类别:
    Operating Grants
Identifying the molecular target for macrophage activation by chlorpyrifos
确定毒死蜱激活巨噬细胞的分子靶标
  • 批准号:
    10555298
  • 财政年份:
    2022
  • 资助金额:
    $ 10.38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了